BSV receives exclusive right to market and distribute NexoBrid in India, for the treatment of severe burns
……To focus on providing safer burn treatments for women and armed forces…..
CHENNAI: Bharat Serums and Vaccines Limited (BSV) a leading biopharmaceutical company in India has entered into an exclusive distribution agreement with MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, for exclusive marketing and distribution of NexoBrid in India. NexoBrid, a new paradigm in treatment of severe burns, is a concentrate of proteolytic enzymes enriched in bromelain, and an easy to use, topically applied product that removes eschar in four hours without harming the surrounding healthy tissues.
Speaking on this, Vishwanath Swarup, COO- Domestic Operations, BSV, said “Burn Treatment and Management continues to remain a public health challenge in India. According to the National health Portal of India, as many as 70 lakh burn injuries are reported with mortality rate as high as 1.4 lakh per year, with almost 91,000 of these being women. As a leading player in the women’s health segment, it is our endeavour to widen access to NexoBrid in India in order to save and improve lives of several women in the country.”
